{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:28:47Z","timestamp":1763468927186,"version":"3.41.2"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Efficient precision vaccines against several highly pathogenic zoonotic viruses are currently lacking. Proteolytic activation is instrumental for a number of these viruses to gain host-cell entry and develop infectivity. For SARS-CoV-2, this process is enhanced by the insertion of a furin cleavage site at the junction of the spike protein S1\/S2 subunits upstream of the metalloprotease TMPRSS2 common proteolytic site. Here, we describe a new approach based on specific epitopes selection from the region involved in proteolytic activation and infectivity for the engineering of precision candidate vaccinating antigens. This approach was developed through its application to the design of SARS-CoV-2 cross-variant candidates vaccinating antigens. It includes an <jats:italic>in silico<\/jats:italic> structural analysis of the viral region involved in infectivity, the identification of conserved immunogenic epitopes and the selection of those eliciting specific immune responses in infected people. The following step consists of engineering vaccinating antigens that carry the selected epitopes and mimic their 3D native structure. Using this approach, we demonstrated through a Covid-19 patient-centered study of a 500 patients\u2019 cohort, that the epitopes selected from SARS-CoV-2 protein S1\/S2 junction elicited a neutralizing antibody response significantly associated with mild and asymptomatic COVID-19 (p&amp;lt;0.001), which strongly suggests protective immunity. Engineered antigens containing the SARS-CoV-2 selected epitopes and mimicking the native epitopes 3D structure generated neutralizing antibody response in mice. Our data show the potential of this combined computational and experimental approach for designing precision vaccines against viruses whose pathogenicity is contingent upon proteolytic activation.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1346349","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:02:23Z","timestamp":1712034143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel approach to designing viral precision vaccines applied to SARS-CoV-2"],"prefix":"10.3389","volume":"14","author":[{"given":"Khaled","family":"Trabelsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noureddin","family":"Ben Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed R.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amany","family":"Elsharkawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Ashoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadok","family":"Chlif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thouraya","family":"Boussoffara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melika","family":"Ben-Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-Dahmani","family":"Fathallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","article-title":"SARS-CoV-2 vaccines: Lights and shadows","volume":"88","author":"Angeli","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)80426-2","article-title":"Viral proteases: evolution of diverse structural motifs to optimize function","volume":"91","author":"Babe","year":"1997","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/(ISSN)1521-4141","article-title":"Enhancement of peptide immunogenicity by linear polymerization","volume":"18","author":"Borras-Cuesta","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/jcmm.16200","article-title":"T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research","volume":"25","author":"Chen","year":"2021","journal-title":"J. Cell Mol. Med."},{"article-title":"Betacoronavirus mRNA vaccine","year":"2020","author":"Ciaramella","key":"B6"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res."},{"article-title":"PyMOL: an open-source molecular graphics tool","year":"2002","author":"Delano","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691715","article-title":"Epitope classification and RBD binding properties of neutralizing antibodies against SARS-coV-2 variants of concern","volume":"12","author":"Deshpande","year":"2021","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1745-6150-8-30","article-title":"Designing of interferon-gamma inducing MHC class-II binders","volume":"8","author":"Dhanda","year":"2013","journal-title":"Biol. Direct"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2023.988109","article-title":"Epitope mapping of SARS-CoV-2 spike protein differentiates the antibody binding activity in vaccinated and infected individuals","volume":"3","author":"Felbinger N","year":"2023","journal-title":"Front. Virol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01120","article-title":"Antibody dependent enhancement due to original antigenic sin and the development of SARS","volume":"11","author":"Fierz","year":"2020","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/v14020187","article-title":"Mucosal vaccines, sterilizing immunity, and the future of SARS-coV-2 virulence","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3839624","article-title":"The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses","author":"F\u00f6hse","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100135","DOI":"10.1074\/jbc.REV120.015980","article-title":"Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection","volume":"296","author":"Fuentes-Prior","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"W35","DOI":"10.1093\/nar\/gkn211","article-title":"PVS: a web server for protein sequence variability analysis tuned to facilitate conserved epitope discovery","volume":"36","author":"Garcia-Boronat","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1038\/s41598-023-35892-0","article-title":"Real time monitoring of COVID-19 intervention effectiveness through contact tracing data","volume":"13","author":"Gibson","year":"2023","journal-title":"Sci. Rep."},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12010020","article-title":"Animal models to test SARS-coV-2 vaccines: which ones are in use and future expectations","volume":"12","author":"Gimenes Lima","year":"2022","journal-title":"Pathogens"},{"key":"B20","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucleic Acids Symp. Ser"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00123-21","article-title":"Bioengineering strategies for developing vaccines against respiratory viral diseases","volume":"35","author":"Iyer","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v11090837","article-title":"The proteolytic regulation of virus cell entry by furin and other proprotein convertases","volume":"11","author":"Izaguirre","year":"2019","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/imm.12889","article-title":"Improved methods for predicting peptide binding affinity to MHC class II molecules","volume":"154","author":"Jensen","year":"2018","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"crossref","first-page":"W24","DOI":"10.1093\/nar\/gkx346","article-title":"BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes","volume":"45","author":"Jespersen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","article-title":"Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis","volume":"591","author":"Johnson","year":"2021","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1080\/21645515.2020.1796425","article-title":"Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19","volume":"16","author":"Karthik","year":"2020","journal-title":"Hum. Vaccin Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nprot.2015.053","article-title":"The Phyre2 web portal for protein modeling, prediction and analysis","volume":"10","author":"Kelley","year":"2015","journal-title":"Nat. Protoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMsr2105280","article-title":"SARS-coV-2 variants and vaccines","volume":"385","author":"Krause","year":"2021","journal-title":"N Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ymthe.2020.10.002","article-title":"Pros and cons of adenovirus-based SARS-coV-2 vaccines","volume":"28","author":"Kremer","year":"2020","journal-title":"Mol. Ther."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00474-22","article-title":"SARS-coV-2 spike furin cleavage site and S2' Basic residues modulate the entry process in a host cell-dependent manner","volume":"96","author":"Lavie","year":"2022","journal-title":"J. Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"104401","DOI":"10.1016\/j.ebiom.2022.104401","article-title":"Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2","volume":"87","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1080\/21645515.2017.1358325","article-title":"Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus","volume":"13","author":"Maslow","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"106012","DOI":"10.1016\/j.pep.2021.106012","article-title":"Linkers: A synergistic way for the synthesis of chimeric proteins","volume":"191","author":"Patel","year":"2022","journal-title":"Protein Expr Purif"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-coV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B43","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J. Allergy Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1016\/j.vaccine.2017.04.082","article-title":"AIDS, Avian flu, SARS, MERS, Ebola, Zika. what next","volume":"35","author":"Reperant","year":"2017","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"W202","DOI":"10.1093\/nar\/gkl343","article-title":"AlgPred: prediction of allergenic proteins and mapping of IgE epitopes","volume":"34","author":"Saha","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.629185","article-title":"SARS-coV-2 proteome-wide analysis revealed significant epitope signatures in COVID-19 patients","volume":"12","author":"Schwarz","year":"2021","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.21.445201","article-title":"Evidence for deleterious antigenic imprinting in SARS-coV-2 immune response","author":"Sen","year":"2021","journal-title":"bioRxiv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"E210","DOI":"10.1503\/jpn","article-title":"Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination","volume":"46","author":"Thompson","year":"2021","journal-title":"J. Psychiatry Neurosci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1001\/jama.2020.8917","article-title":"Adverse consequences of rushing a SARS-coV-2 vaccine: implications for public trust","volume":"323","author":"Trogen","year":"2020","journal-title":"JAMA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02130","article-title":"Viral emerging diseases: challenges in developing vaccination strategies","volume":"11","author":"Trovato","year":"2020","journal-title":"Front. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1021\/acs.jpclett.0c01698","article-title":"Structure of furin protease binding to SARS-coV-2 spike glycoprotein and implications for potential targets and virulence","volume":"11","author":"Vankadari","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-coV-2 spike glycoprotein","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-coV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"110231","DOI":"10.1016\/j.mehy.2020.110231","article-title":"COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight","volume":"144","author":"Wiese","year":"2020","journal-title":"Med. Hypotheses"},{"key":"B55","doi-asserted-by":"publisher","first-page":"W174","DOI":"10.1093\/nar\/gkv342","article-title":"I-TASSER server: new development for protein structure and function predictions","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00284-022-02800-0","article-title":"Long-term persistence of anti-SARS-COV-2 igG antibodies","volume":"79","author":"Yousefi","year":"2022","journal-title":"Curr. Microbiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-coV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"12370","DOI":"10.1021\/acsnano.0c06109","article-title":"Engineering antiviral vaccines","volume":"14","author":"Zhou","year":"2020","journal-title":"ACS Nano"},{"key":"B59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.0105-2896.2006.00402.x","article-title":"Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'","volume":"211","author":"Zinkernagel","year":"2006","journal-title":"Immunol. Rev."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1346349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:02:27Z","timestamp":1712034147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1346349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":59,"alternative-id":["10.3389\/fcimb.2024.1346349"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1346349","relation":{},"ISSN":["2235-2988"],"issn-type":[{"type":"electronic","value":"2235-2988"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"1346349"}}